BiotechTube

Niravam + SSRI/SNRI

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Generalized Anxiety Disorder

Conditions

Generalized Anxiety Disorder, Panic Disorder

Trial Timeline

Oct 1, 2005 → Jun 1, 2006

NCT ID
NCT00266409

About Niravam + SSRI/SNRI

Niravam + SSRI/SNRI is a approved stage product being developed by UCB for Generalized Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00266409. Target conditions include Generalized Anxiety Disorder, Panic Disorder.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00266409ApprovedCompleted

Competing Products

20 competing products in Generalized Anxiety Disorder

See all competitors
ProductCompanyStageHype Score
atomoxetine + placeboEli LillyPhase 2/3
65
SatralizumabChugai PharmaceuticalPhase 3
77
PerampanelEisaiPre-clinical
23
Perampanel + Placebo comparatorEisaiPhase 3
77
zonisamideEisaiPre-clinical
23
FycompaEisaiPre-clinical
23
FycompaEisaiPre-clinical
23
PerampanelEisaiPhase 3
77
PerampanelEisaiPre-clinical
23
CenobamateOno PharmaceuticalPhase 3
77
Duloxetine + PlaceboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyApproved
85
IxekizumabEli LillyApproved
85
eszopiclone + eszopiclone + PlaceboSumitomo PharmaPhase 2
52
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
85
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)AbbViePhase 2
52
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/dayAbbViePhase 2
52
ABBV-932 + PlaceboAbbViePhase 1
33
EscitalopramAbbVieApproved
85
AdalimumabAbbViePhase 3
77

Other Products from UCB

LevetiracetamApproved
82
Parcopa + carbidopa-levodopa (Sinemet)Approved
82
LevocetirizineApproved
82
RotigotineApproved
82
Levetiracetam + OxcarbazepineApproved
82